Deadline: 29-Oct-2025
The Breakthrough T1D has launched a major funding opportunity aimed at advancing therapies that can improve cardiovascular outcomes for individuals living with type 1 diabetes (T1D).
With cardiovascular disease (CVD) being a leading cause of morbidity and mortality among people with T1D, this initiative focuses on accelerating clinical trials that explore innovative therapies, whether newly developed, repurposed, or already approved for other conditions.
The program seeks proposals for trials that address heart failure and broader cardiovascular complications in T1D populations. Priority will be given to studies built around mechanistic or surrogate endpoints, offering a pathway to generate faster, actionable insights. Applicants are encouraged to assess the current research landscape to ensure proposals are complementary and not duplicative of ongoing studies.
Potential areas of focus include proof-of-concept and pilot trials, stratified patient studies, and evaluations of therapies targeting T1D-specific aspects of cardiovascular disease such as autoimmunity. Innovative trial designs that tackle the feasibility challenges of traditional CVD research are welcomed, as are ancillary studies to existing trials and post-hoc analyses of T1D participants in broader cardiovascular studies. Additionally, this funding aims to encourage inclusion of T1D patients in company-sponsored or non-T1D cardiovascular trials, ensuring their needs are better represented in clinical science.
Grants of up to $3 million over a three-year period will be awarded to support these efforts. Both academic investigators and industry partners are eligible to apply, with domestic and international applications welcomed. Applicants must hold advanced degrees such as an M.D., Ph.D., or equivalent and be affiliated with a recognized research institution.
By prioritizing innovative, targeted, and collaborative clinical research, Breakthrough T1D aims to not only advance scientific understanding but also deliver meaningful therapies that address the urgent cardiovascular risks faced by people with T1D. This funding opportunity represents a critical step in bridging gaps between diabetes care and cardiovascular health while supporting diverse investigators committed to transformative solutions.
For more information, visit Breakthrough T1D.